{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:04:03Z","timestamp":1785942243480,"version":"3.56.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1038\/s41375-022-01673-3","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T07:05:29Z","timestamp":1661843129000},"page":"2453-2460","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients"],"prefix":"10.1038","volume":"36","author":[{"given":"Barbara","family":"Mora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1809-284X","authenticated-orcid":false,"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kuykendall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7572-9504","authenticated-orcid":false,"given":"Elisa","family":"Rumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Maffioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8367-5668","authenticated-orcid":false,"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5178-5827","authenticated-orcid":false,"given":"Valerio","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Caramella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Salmoiraghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Kiladjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4401-0812","authenticated-orcid":false,"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2664-8131","authenticated-orcid":false,"given":"Francisco","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8524-0964","authenticated-orcid":false,"given":"Richard T.","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7926-6052","authenticated-orcid":false,"given":"Francesco","family":"Albano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Benevolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7171-2935","authenticated-orcid":false,"given":"David M.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo G.","family":"Della Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6881-417X","authenticated-orcid":false,"given":"Timothy","family":"Devos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Rotunno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1876-5269","authenticated-orcid":false,"given":"Rami S.","family":"Komrokji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria C.","family":"Casetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0905-5927","authenticated-orcid":false,"given":"Michele","family":"Merli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Brociner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenica","family":"Caramazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Auteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2747-6327","authenticated-orcid":false,"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Bert\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Arcaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8068-5289","authenticated-orcid":false,"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"1673_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"1673_CR2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","volume":"66","author":"JJ O\u2019Shea","year":"2015","unstructured":"O\u2019Shea JJ, Schwartz DM, Villarino AV, Gadina M, MCInnes IB, Laurence A. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311\u201328.","journal-title":"Annu Rev Med"},{"key":"1673_CR3","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1182\/blood-2013-09-527903","volume":"123","author":"HL Geyer","year":"2014","unstructured":"Geyer HL, Scherber RM, Dueck AC, Kiladjian J-J, Xiao Z, Slot S, et al. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood. 2014;123:3803\u201310.","journal-title":"Blood"},{"key":"1673_CR4","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1182\/blood-2017-01-761999","volume":"129","author":"P Guglielmelli","year":"2017","unstructured":"Guglielmelli P, Pacilli A, Rotunno G, Rumi E, Rosti V, Delaini F, et al. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood. 2017;129:3227\u201336.","journal-title":"Blood"},{"key":"1673_CR5","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/sj.leu.2404914","volume":"22","author":"G Barosi","year":"2008","unstructured":"Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Versovsek S, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22:437\u20138.","journal-title":"Leukemia"},{"key":"1673_CR6","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.leukres.2018.04.012","volume":"69","author":"B Mora","year":"2018","unstructured":"Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, et al. Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. Leuk Res. 2018;69:100\u20132.","journal-title":"Leuk Res"},{"key":"1673_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.7326\/M17-0028","volume":"168","author":"M Hultcrantz","year":"2018","unstructured":"Hultcrantz M, Bj\u00f6rkholm M, Dickman PW, Landgren O, Derolf \u00c5R, Kristinsson SY, et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med. 2018;168:317\u201325.","journal-title":"Ann Intern Med"},{"key":"1673_CR8","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1182\/blood.2020008043","volume":"137","author":"AR Moliterno","year":"2021","unstructured":"Moliterno AR, Ginzburg YZ, Hoffman R. Clinical insights into the origins of thrombosis in myeloproliferative neoplasms. Blood. 2021;137:1145\u201353.","journal-title":"Blood"},{"key":"1673_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5387-9","volume":"19","author":"T Rungjirajittranon","year":"2019","unstructured":"Rungjirajittranon T, Owattanapanich W, Ungprasert P, Siritanaratkul N, Ruchutrakool T. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms. BMC Cancer. 2019;19:184.","journal-title":"BMC Cancer"},{"key":"1673_CR10","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1182\/bloodadvances.2020002414","volume":"4","author":"PE Debureaux","year":"2020","unstructured":"Debureaux PE, Cassinat B, Soret-Dulphy J, Mora B, Verger E, Maslah N, et al. Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses. Blood Adv. 2020;4:3708\u201315.","journal-title":"Blood Adv"},{"key":"1673_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.thromres.2014.03.040","volume":"134","author":"F Dentali","year":"2014","unstructured":"Dentali F, Ageno W, Rumi E, Casetti I, Poli D, Scoditti U, et al. Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases. Thromb Res. 2014;134:41\u20133.","journal-title":"Thromb Res"},{"key":"1673_CR12","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1002\/ajh.26336","volume":"96","author":"N Gangat","year":"2021","unstructured":"Gangat N, Guglielmelli P, Betti S, Farrukh F, Carobbio A, Barbui T, et al. Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases. Am J Hematol. 2021;96:1580\u20136.","journal-title":"Am J Hematol"},{"key":"1673_CR13","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1200\/JCO.2014.57.6652","volume":"33","author":"M Hultcrantz","year":"2015","unstructured":"Hultcrantz M, Wilkes SR, Kristinsson SY, Andersson TM-L, Derolf AR, Eloranta S, et al. Risk and cause of death in patients diagnosed with myeloproliferative neoplasms in Sweden between 1973 and 2005: a population-based study. J Clin Oncol. 2015;33:2288\u201395.","journal-title":"J Clin Oncol"},{"key":"1673_CR14","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","volume":"119","author":"HC Hasselbalch","year":"2012","unstructured":"Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012;119:3219\u201325.","journal-title":"Blood"},{"key":"1673_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-017-0425-z","volume":"10","author":"F Lussana","year":"2017","unstructured":"Lussana F, Carobbio A, Salmoiraghi S, Guglielmelli P, Vannucchi AM, Bottazzi B, et al. Driver mutations (JAK2V617F, MPLW515L\/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. J Hematol Oncol. 2017;10:54.","journal-title":"J Hematol Oncol"},{"key":"1673_CR16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3324\/haematol.2018.195321","volume":"104","author":"A Guy","year":"2019","unstructured":"Guy A, Gourdou-Latyszenok V, Le Lay N, Peghaire C, Kilani B, Vieira Dias J, et al. Vascular endothelial cell expression of JAK2 V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression. Haematologica. 2019;104:70\u201381.","journal-title":"Haematologica"},{"key":"1673_CR17","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","volume":"115","author":"T Barbui","year":"2010","unstructured":"Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood. 2010;115:778\u201382.","journal-title":"Blood."},{"key":"1673_CR18","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","volume":"123","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123:1544\u201351.","journal-title":"Blood"},{"key":"1673_CR19","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1182\/blood-2014-08-596676","volume":"124","author":"G Finazzi","year":"2014","unstructured":"Finazzi G, Carobbio A, Guglielmelli P, Cavalloni C, Salmoiraghi S, Vannucchi AM, et al. Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. Blood. 2014;124:2611\u20132.","journal-title":"Blood"},{"key":"1673_CR20","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","volume":"124","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Pascutto C, Guglielmelli P, Mart\u00ednez-Trillos A, Casetti I, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124:1062\u20139.","journal-title":"Blood"},{"key":"1673_CR21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1056\/NEJMoa035572","volume":"350","author":"R Landolfi","year":"2004","unstructured":"Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N. Engl J Med. 2004;350:114\u201324.","journal-title":"N. Engl J Med"},{"key":"1673_CR22","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"R Marchioli","year":"2005","unstructured":"Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005;23:2224\u201332.","journal-title":"J Clin Oncol"},{"key":"1673_CR23","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.3324\/haematol.13346","volume":"93","author":"F Passamonti","year":"2008","unstructured":"Passamonti F, Rumi E, Arcaini L, Boveri E, Elena C, Pietra D, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008;93:1645\u201351.","journal-title":"Haematologica"},{"key":"1673_CR24","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","volume":"117","author":"A Carobbio","year":"2011","unstructured":"Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117:5857\u20139.","journal-title":"Blood"},{"key":"1673_CR25","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1182\/blood-2021-145116","volume":"138","author":"T Barbui","year":"2021","unstructured":"Barbui T, Ghirardi A, Carobbio A, Masciulli A, Carioli G, Rambaldi A, et al. The interaction between IPSS score and JAK2 mutation identifies patients at different vascular risk in primary myelofibrosis. abstract from the 2021 American Society of Hematology (ASH) congress. Blood. 2021;138:236.","journal-title":"Blood"},{"key":"1673_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0289-2","volume":"10","author":"P Guglielmelli","year":"2020","unstructured":"Guglielmelli P, Carobbio A, Rumi E, De Stefano V, Mannelli L, Mannelli F, et al. Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. Blood Cancer J. 2020;10:21.","journal-title":"Blood Cancer J"},{"key":"1673_CR27","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/ajh.24377","volume":"91","author":"G Rotunno","year":"2016","unstructured":"Rotunno G, Pacilli A, Artusi V, Rumi E, Maffioli M, Delaini F, et al. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group. Am J Hematol. 2016;91:681\u20136.","journal-title":"Am J Hematol"},{"key":"1673_CR28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","volume":"9","author":"A Kaifie","year":"2016","unstructured":"Kaifie A, Kirschner M, Wolf D, Maintz C, Haenel M, Gattermann N, et al. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol. 2016;9:18.","journal-title":"J Hematol Oncol"},{"key":"1673_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.thromres.2022.02.006","volume":"212","author":"G Teng","year":"2022","unstructured":"Teng G, Zhou Y, Zhang Y, Hu N, Liu T, Han Y, et al. Thrombosis in patients with post-polycythemia myelofibrosis: incidence and risk factors. Thromb Res. 2022;212:38\u201343.","journal-title":"Thromb Res"},{"key":"1673_CR30","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/leu.2016.351","volume":"31","author":"F Passamonti","year":"2017","unstructured":"Passamonti F, Mora B, Giorgino T, Guglielmelli P, Cazzola M, Maffioli M, et al. Driver mutations\u2019 effect in secondary myelofibrosis: an international multicenter study based on 781 patients. Leukemia. 2017;31:970\u20133.","journal-title":"Leukemia"},{"key":"1673_CR31","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1038\/leu.2017.169","volume":"31","author":"F Passamonti","year":"2017","unstructured":"Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017;31:2726\u201331.","journal-title":"Leukemia"},{"key":"1673_CR32","doi-asserted-by":"publisher","first-page":"e392","DOI":"10.3324\/haematol.2017.185751","volume":"103","author":"B Mora","year":"2018","unstructured":"Mora B, Giorgino T, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, et al. Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. Haematologica. 2018;103:e392\u20134.","journal-title":"Haematologica"},{"key":"1673_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0128-x","volume":"8","author":"D Barraco","year":"2018","unstructured":"Barraco D, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, et al. Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. Blood Cancer J. 2018;8:89.","journal-title":"Blood Cancer J"},{"key":"1673_CR34","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/ajh.25644","volume":"95","author":"B Mora","year":"2020","unstructured":"Mora B, Guglielmelli P, Rumi E, Maffioli M, Barraco D, Rambaldi A, et al. Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group. Am J Hematol. 2020;95:E1\u20133.","journal-title":"Am J Hematol"},{"key":"1673_CR35","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057\u201369.","journal-title":"Leukemia"},{"key":"1673_CR36","unstructured":"Network NCC Myeloproliferative neoplasms. 2022 [Available from https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpn.pdf]."},{"key":"1673_CR37","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1182\/blood-2014-07-591610","volume":"124","author":"T Barbui","year":"2014","unstructured":"Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F, et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood. 2014;124:3021\u20133.","journal-title":"Blood"},{"key":"1673_CR38","doi-asserted-by":"publisher","first-page":"1068809","DOI":"10.1016\/j.leukres.2022.106809","volume":"115","author":"N Pemmaraju","year":"2022","unstructured":"Pemmaraju N, Gerds AT, Yu J, Parasuraman S, Shan A, Xi A, et al. Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia. Leuk Res. 2022;115:1068809.","journal-title":"Leuk Res"},{"key":"1673_CR39","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29:3179\u201384.","journal-title":"J Clin Oncol"},{"key":"1673_CR40","doi-asserted-by":"publisher","first-page":"101735","DOI":"10.18632\/oncotarget.21594","volume":"8","author":"E Rumi","year":"2017","unstructured":"Rumi E, Boveri E, Bellini M, Pietra D, Ferretti VV, Sant\u2019Antonio E, et al. Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. Oncotarget. 2017;8:101735\u201344.","journal-title":"Oncotarget"},{"key":"1673_CR41","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115:1703\u20138.","journal-title":"Blood"},{"key":"1673_CR42","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/leu.2010.148","volume":"24","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24:1574\u20139.","journal-title":"Leukemia"},{"key":"1673_CR43","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1182\/blood-2021-148509","volume":"138","author":"AT Gerds","year":"2021","unstructured":"Gerds AT, Mesa RA, Burke JM, Grunwald MR, Stein BL, Scherber R, et al. A real-world evaluation of the association between elevated blood counts and thrombotic events in polycythemia vera (Analysis of Data from the REVEAL Study). Abstract from the 2021 American Society of Hematology (ASH) Congress. Blood. 2021;138:239.","journal-title":"Blood."},{"key":"1673_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00581-6","volume":"11","author":"P Guglielmelli","year":"2021","unstructured":"Guglielmelli P, Loscocco GG, Mannarelli C, Rossi E, Mannelli F, Ramundo F, et al. JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis. Blood Cancer J. 2021;11:199.","journal-title":"Blood Cancer J"},{"key":"1673_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00625-5","volume":"12","author":"A Carobbio","year":"2022","unstructured":"Carobbio A, Vannucchi AM, De Stefano V, Masciulli A, Guglielmelli P, Loscocco GG, et al. Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera. Blood Cancer J. 2022;12:28.","journal-title":"Blood Cancer J"},{"key":"1673_CR46","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120:5128\u201333.","journal-title":"Blood"},{"key":"1673_CR47","first-page":"e369","volume":"5","author":"T Barbui","year":"2015","unstructured":"Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood. Cancer J. 2015;5:e369.","journal-title":"Cancer J"},{"key":"1673_CR48","doi-asserted-by":"publisher","first-page":"E35","DOI":"10.1002\/ajh.26423","volume":"97","author":"F Farrukh","year":"2022","unstructured":"Farrukh F, Guglielmelli P, Loscocco GG, Pardanani AD, Hanson CA, De Stefano V, et al. Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia. Am J Hematol. 2022;97:E35\u20137.","journal-title":"Am J Hematol"},{"key":"1673_CR49","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/leu.2014.343","volume":"29","author":"MC Finazzi","year":"2015","unstructured":"Finazzi MC, Carobbio A, Cervantes F, Isola IM, Vannucchi AM, Guglielmelli P, et al. CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis. Leukemia. 2015;29:1209\u201310.","journal-title":"Leukemia"},{"key":"1673_CR50","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.2217\/fon-2022-0276","volume":"18","author":"D Tremblay","year":"2022","unstructured":"Tremblay D, Mesa R. Momelotinib for the treatment of myelofibrosis with anemia. Future Oncol. 2022;18:2559\u201371.","journal-title":"Future Oncol"},{"key":"1673_CR51","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","volume":"7","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchokova L, Egyed M, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7:e196\u2013208.","journal-title":"Lancet Haematol"},{"key":"1673_CR52","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1038\/s41375-021-01183-8","volume":"35","author":"G Abu-Zeinah","year":"2021","unstructured":"Abu-Zeinah G, Krichevsky S, Cruz T, Hoberman G, Jaber D, Savage N, et al. Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. Leukemia. 2021;35:2592\u2013601.","journal-title":"Leukemia"},{"key":"1673_CR53","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1016\/S2352-3026(20)30373-2","volume":"8","author":"T Barbui","year":"2021","unstructured":"Barbui T, Vannucchi AM, De Stefano V, Masciulli A, Carobbio A, Ferrari A, et al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. Lancet Haematol. 2021;8:e175\u201384.","journal-title":"Lancet Haematol"},{"key":"1673_CR54","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","volume":"9","author":"M Marchetti","year":"2022","unstructured":"Marchetti M, Vannucchi AM, Griesshammer M, Harrison C, Koschmieder S, Gisslinger H, et al. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol. 2022;9:e301\u201311.","journal-title":"Lancet Haematol"},{"key":"1673_CR55","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1016\/S2352-3026(19)30207-8","volume":"7","author":"J-J Kiladjian","year":"2020","unstructured":"Kiladjian J-J, Zachee P, Hino M, Pane F, Masszi T, Harrison CN, et al. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol. 2020;7:e226\u201337.","journal-title":"Lancet Haematol"},{"key":"1673_CR56","doi-asserted-by":"publisher","first-page":"e480","DOI":"10.1016\/S2352-3026(22)00102-8","volume":"9","author":"F Passamonti","year":"2022","unstructured":"Passamonti F, Palandri F, Saydam G, Callum J, Devos T, Guglielmelli P, et al. Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study. Lancet Haematol. 2022;9:e480\u201392.","journal-title":"Lancet Haematol"},{"key":"1673_CR57","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1182\/bloodadvances.2019001158","volume":"4","author":"A Masciulli","year":"2020","unstructured":"Masciulli A, Ferrari A, Carobbio A, Ghirardi A, Barbui T. Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2020;4:380\u20136.","journal-title":"Blood Adv"},{"key":"1673_CR58","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1182\/blood-2019-03-900860","volume":"133","author":"F Passamonti","year":"2019","unstructured":"Passamonti F. Stem cell transplant in MF: it\u2019s time to personalize. Blood. 2019;133:2118\u201320.","journal-title":"Blood"},{"key":"1673_CR59","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017;10:55.","journal-title":"J Hematol Oncol"},{"key":"1673_CR60","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1182\/bloodadvances.2021006006","volume":"6","author":"P Guglielmelli","year":"2022","unstructured":"Guglielmelli P, Ghirardi A, Carobbio A, Masciulli A, Maccari C, Mora B, et al. Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of ERNEST Study. Blood Adv. 2022;6:373\u20135.","journal-title":"Blood Adv"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01673-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01673-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01673-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T14:04:19Z","timestamp":1666620259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01673-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":60,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1673"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01673-3","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,30]]},"assertion":[{"value":"7 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}